These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 30550799

  • 1. Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs.
    Garg R, Latimer L, Gomis S, Gerdts V, Potter A, van Drunen Littel-van den Hurk S.
    Antiviral Res; 2019 Feb; 162():54-60. PubMed ID: 30550799
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity.
    Garg R, Brownlie R, Latimer L, Gerdts V, Potter A, van Drunen Littel-van den Hurk S.
    Vaccine; 2017 Dec 18; 35(51):7139-7146. PubMed ID: 29153777
    [Abstract] [Full Text] [Related]

  • 4. Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs.
    Garg R, Latimer L, Wang Y, Simko E, Gerdts V, Potter A, van Drunen Littel-van den Hurk S.
    Vaccine; 2016 Jan 04; 34(2):261-269. PubMed ID: 26616551
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC, McAuliffe JM, Murphy BR, Collins PL.
    J Virol; 2001 May 04; 75(10):4594-603. PubMed ID: 11312329
    [Abstract] [Full Text] [Related]

  • 8. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B, Ngwuta JO, Herbert R, Swerczek J, Dorward DW, Amaro-Carambot E, Mackow N, Kabatova B, Lingemann M, Surman S, Yang L, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Schaap-Nutt A, Collins PL, Munir S.
    J Virol; 2016 Nov 01; 90(21):10022-10038. PubMed ID: 27581977
    [Abstract] [Full Text] [Related]

  • 9. Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus.
    Garg R, Latimer L, Gerdts V, Potter A, van Drunen Littel-van den Hurk S.
    Hum Vaccin Immunother; 2017 Dec 02; 13(12):2894-2901. PubMed ID: 28825870
    [Abstract] [Full Text] [Related]

  • 10. Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity.
    Garg R, Latimer L, Gerdts V, Potter A, van Drunen Littel-van den Hurk S.
    J Gen Virol; 2014 May 02; 95(Pt 5):1043-1054. PubMed ID: 24572813
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
    Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, Henderson FW, Meissner HC, Madhi S, Roberton D, Marshall H, Loh R, Sly P, Murphy B, Tatem JM, Randolph V, Hackell J, Gruber W, Tsai TF.
    J Infect Dis; 2004 Dec 15; 190(12):2096-103. PubMed ID: 15551207
    [Abstract] [Full Text] [Related]

  • 12. Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV.
    Haller AA, Mitiku M, MacPhail M.
    J Gen Virol; 2003 Aug 15; 84(Pt 8):2153-2162. PubMed ID: 12867647
    [Abstract] [Full Text] [Related]

  • 13. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B, Surman S, Amaro-Carambot E, Kabatova B, Mackow N, Lingemann M, Yang L, McLellan JS, Graham BS, Kwong PD, Schaap-Nutt A, Collins PL, Munir S.
    J Virol; 2015 Sep 15; 89(18):9499-510. PubMed ID: 26157122
    [Abstract] [Full Text] [Related]

  • 14. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.
    Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, Lawlor HA, Guzzetta JM, Spaete RR, Haller AA.
    J Virol; 2004 Oct 15; 78(20):11198-207. PubMed ID: 15452239
    [Abstract] [Full Text] [Related]

  • 15. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
    Tao T, Davoodi F, Cho CJ, Skiadopoulos MH, Durbin AP, Collins PL, Murphy BR.
    Vaccine; 2000 Jan 31; 18(14):1359-66. PubMed ID: 10618533
    [Abstract] [Full Text] [Related]

  • 16. Formulation of the respiratory syncytial virus fusion protein with a polymer-based combination adjuvant promotes transient and local innate immune responses and leads to improved adaptive immunity.
    Sarkar I, Garg R, van Drunen Littel-van den Hurk S.
    Vaccine; 2016 Sep 30; 34(42):5114-5124. PubMed ID: 27591951
    [Abstract] [Full Text] [Related]

  • 17. Current status of vaccines for parainfluenza virus infections.
    Sato M, Wright PF.
    Pediatr Infect Dis J; 2008 Oct 30; 27(10 Suppl):S123-5. PubMed ID: 18820572
    [Abstract] [Full Text] [Related]

  • 18. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE, Patel N, Lu H, Liu Y, Guebre-Xabier M, Piedra PA, Glenn G, Ellingsworth L, Smith G.
    Vaccine; 2018 Dec 18; 36(52):8069-8078. PubMed ID: 30389195
    [Abstract] [Full Text] [Related]

  • 19. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N, Amaro-Carambot E, Liang B, Surman S, Lingemann M, Yang L, Collins PL, Munir S.
    J Virol; 2015 Oct 18; 89(20):10319-32. PubMed ID: 26223633
    [Abstract] [Full Text] [Related]

  • 20. Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge.
    Welliver RC, Papin JF, Preno A, Ivanov V, Tian JH, Lu H, Guebre-Xabier M, Flyer D, Massare MJ, Glenn G, Ellingsworth L, Smith G.
    Vaccine; 2020 Jan 29; 38(5):1258-1270. PubMed ID: 31761502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.